Statistics from Altmetric.com
Agmon-Levin et al1 formulated recommendations for the assessment of antinuclear antibodies (ANA). Indirect immunofluorescence (IIF) is considered the reference method for ANA screening, which is in agreement with the American College of Rheumatology (ACR) position statement.2 The recommendations are based on current knowledge and expert experience. However, as recognised by Meroni and Schur,2 no well-planned studies comparing the diagnostic accuracy of the old IIF and the new methods have been undertaken.
In a recent study, IIF was compared to a new automated method for connective disease screening (fluoroenzymeimmunoassay (FEIA) (EliA CTD screen, Thermo Fisher)) using samples obtained at the time of diagnosis from well-characterised patients and controls.3 Diagnostic accuracy data (for systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and Sjögren's syndrome (SS)) from this study is recapitulated in table 1. …
Contributors XB: drafted the manuscript. SF: performed the ROC analyses, critically revised the manuscript.
Competing interests XB is a senior clinical investigator of the Fund for Scientific Research—Flanders. XB has received a lecture fee from Thermo Fisher.
Ethics approval Ethics Committee University Hospital Leuven.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.